REG - Diaceutics PLC - Capital Markets Webinar

DiaceuticsAnnouncement

05/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241105:nRSE7065Ka&default-theme=true

RNS Number : 7065K  Diaceutics PLC  05 November 2024

Diaceutics - PMx Capital Markets Webinar - Wednesday, 4 December 2024

 

Belfast and London, 5 November 2024 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, will host a virtual Capital
Markets Event for analysts and investors to discuss PMx - a suite of data and
knowledge driven services built to revolutionise the commercialisation of
precision medicines by removing barriers to access and adoption, on Wednesday,
4 December 2024 at 1400-1530 GMT (0900-1030 ET).

 

The event will include presentations from senior Diaceutics managers and
external PMx partners. The purpose of the event will be to give analysts and
investors a deeper insight into the DXRX platform and Diaceutics recently
launched PMx service which enables Diaceutics' customers to unlock more value
from their product commercialisation and also allows Diaceutics a greater
share and participation in this value creation.

 

To register your interest in attending, please use the following link:

 

https://us06web.zoom.us/webinar/register/WN_aIuutKaZQrSEYpRDVdr7bg
(https://us06web.zoom.us/webinar/register/WN_aIuutKaZQrSEYpRDVdr7bg)

 

 

Enquiries:

 

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZMGMNMLGDZM